Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study

Authors: Gemma Bruera, Alessandra Santomaggio, Katia Cannita, Paola Lanfiuti Baldi, Marianna Tudini, Federica De Galitiis, Maria Mancini, Paolo Marchetti, Adelmo Antonucci, Corrado Ficorella, Enrico Ricevuto

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

This phase II study investigated efficacy and safety of weekly alternating Bevacizumab (BEV)/Irinotecan (CPT-11) or Oxaliplatin (OHP) associated to weekly 5-Fluorouracil (5-FU) in first line treatment of metastatic colorectal carcinoma (MCRC).

Methods

Simon two-step design: delta 20% (p0 50%, p1 70%), power 80%, α 5%, β 20%. Projected objective responses (ORR): I step, 8/15 patients (pts); II step 26/43 pts. Schedule: weekly 12 h-timed-flat-infusion/5-FU 900 mg/m2, days 1-2, 8-9, 15-16, 22-23; CPT-11 160 mg/m2 plus BEV 5 mg/kg, days 1,15; OHP at three dose-levels, 60-70-80 mg/m2, days 8, 22; every 4 weeks.

Results

Fifty consecutive, unselected pts < 75 years were enrolled: median age 63; young-elderly (yE) 24 (48%); liver metastases (LM) 33 pts, 66% Achieved OHP recommended dose, 80 mg/m2. ORR 82% intent-to-treat and 84% as-treated analysis. Median progression-free survival 12 months. Equivalent efficacy was obtained in yE pts. Liver metastasectomies were performed in 26% of all pts and in 39% of pts with LM. After a median follow-up of 21 months, median overall survival was 28 months. Cumulative G3-4 toxicities per patient: diarrhea 28%, mucositis 6%, neutropenia 10%, hypertension 2%. They were equivalent in yE pts. Limiting toxicity syndromes (LTS), consisting of the dose-limiting toxicity, associated or not to G2 or limiting toxicities: 44% overall, 46% in yE. Multiple versus single site LTS, respectively: overall, 24% versus 20%; yE pts, 37.5% versus 8%.

Conclusion

Poker combination shows high activity and efficacy in first line treatment of MCRC. It increases liver metastasectomies rate and can be safely administered.

Trial registration

Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali (OsSC) Agenzia Italiana del Farmaco (AIFA) Numero EudraCT 2007-004946-34
Appendix
Available only for authorised users
Literature
1.
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GY, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000, 343: 905-914. 10.1056/NEJM200009283431302.CrossRefPubMed
2.
Douillard JY, Cunningham D, Roth AD, Navarro M, James R, Karasek P, Jandik P, Iveson F, Carmichael J, Alaki M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000, 355: 1041-1047. 10.1016/S0140-6736(00)02034-1.CrossRefPubMed
3.
Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000, 18 (1): 136-47.PubMed
4.
De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000, 18: 2938-2967.PubMed
5.
Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R, Italian Trials in Medical Oncology (I.T.M.O.) Group: Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer. 2004, 100 (2): 279-87. 10.1002/cncr.11910.CrossRefPubMed
6.
Comella P, Natale D, Farris A, Gambardella A, Maiorino L, Massida B, Cesaretti R, Tafuto S, Lorusso V, Leo S, Cannone M: Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. Final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer. 2005, 104: 282-289. 10.1002/cncr.21167.CrossRefPubMed
7.
Grothey A, Goetz MP: Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. Clin Colorectal Cancer. 2004, 4 (Suppl 1): S37-42. 10.3816/CCC.2004.s.006.CrossRefPubMed
8.
Kabbinavar FF, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003, 21 (1): 60-65. 10.1200/JCO.2003.10.066.CrossRefPubMed
9.
Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005, 23 (16): 3706-3712. 10.1200/JCO.2005.00.232.CrossRefPubMed
10.
Hurwitz HI, Fehrenbacher L, Hainsworth J, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar FF: Bevacizumab in combination with fluorouracil and leucoverin: an alternative regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005, 23: 3502-3508. 10.1200/JCO.2005.10.017.CrossRefPubMed
11.
Hurwitz HI, Fehrenbacher L, Novotny WF, Cartwright T, Hainsworth J, Meropol NJ, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross M, Kabbinavar FF: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350 (23): 2335-234. 10.1056/NEJMoa032691.CrossRefPubMed
12.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and Cetuximab plus Irinotecan in Irinotecan refractory metastatic colorectal cancer. N Engl J Med. 2004, 351: 337-45. 10.1056/NEJMoa033025.CrossRefPubMed
13.
Hochster HS, Hart LL, Ramanathan RK, Barrett HC, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, abubakr Y, Saif MW, Schwartzeberg L: Safety and efficacy of Oxaliplatin-Fluoropyrimidine regimens with or without Bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Results of the TREE study. J Clin Oncol. 2008, 26: 3523-3529. 10.1200/JCO.2007.15.4138.CrossRefPubMed
14.
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, sirzen F, Cassidy J: Bevacizumab in combination with Oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008, 26: 2013-2019. 10.1200/JCO.2007.14.9930.CrossRefPubMed
15.
Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T: Bevacizumab, Capecitabine, and Oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008, 26: 1830-1835. 10.1200/JCO.2007.13.7679.CrossRefPubMed
16.
Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Di Bartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D, First BEAT investigators: Safety and efficacy of first-line Bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009, 20 (11): 1842-7. 10.1093/annonc/mdp233.CrossRefPubMed
17.
Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G: Phase III trial of infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) compared with infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007, 25: 1670-1676. 10.1200/JCO.2006.09.0928.CrossRefPubMed
18.
Souglakos J, Andrulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kalolyris S, Tsousis S, Kouroussis CH, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V: FOLFOXIRI (folin acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folin acid, 5-fluorouracil and irinotecan) as first-line treatment in metestatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). British Journal of Cancer. 2006, 94: 798-805. 10.1038/sj.bjc.6603011.CrossRefPubMedPubMedCentral
19.
Ficorella C, Ricevuto E, Morelli MF, Morese R, Cannita K, Cianci G, Di Rocco ZC, De Galitiis F, De Tursi M, Tinari N, Iacobelli S, Marchetti P: Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study. Oncol Rep. 2006, 15 (5): 1345-1350.PubMed
20.
Garufi C, Lévi F, Aschelter AM, Pace R, Giunta S, Nisticò C, Gallà DA, Silecchia GF, Franchi F, Narduzzi C, Terzoli E: A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and l-folinic acid in patients with metastatic colorectal cancer. Eur J Cancer. 1997, 33: 1566-71. 10.1016/S0959-8049(97)00133-0.CrossRefPubMed
21.
Cure H, Chevalier V, Pezet D, Bousquet J, Focan C, Levi F, Garufi C, Chipponi J, Chollet P: Phase II trial of chronomodulated infusion of 5-fluorouracil and l-folinic acid in metastatic colorectal cancer. Anticancer Res. 2000, 20: 4649-4654.PubMed
22.
Morelli MF, Santomaggio A, Ricevuto E, Cannita K, De Galitiis F, Tudini M, Bruera G, Mancini M, Pelliccione M, Calista F, Guglielmi F, Martella F, Lanfiuti Baldi P, Porzio G, Russo A, Gebbia N, Iacobelli S, Marchetti P, Ficorella C, CINBO (Consorzio Interuniversitario Nazionale per la Bio-Oncologia): Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in Advanced Colorectal Cancer: a dose-finding and phase II study. Oncol Rep. 2010, 23 (6): 1635-40.PubMed
23.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92: 205-216. 10.1093/jnci/92.3.205.CrossRefPubMed
24.
Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J am Stat Assoc. 1958, 53: 457-481. 10.2307/2281868.CrossRef
25.
Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989, 10: 1-10. 10.1016/0197-2456(89)90015-9.CrossRefPubMed
26.
Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC: Accelereted titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997, 89 (15): 1138-47. 10.1093/jnci/89.15.1138.CrossRefPubMed
27.
Masi G, Salvatore L, Fornaro L, Vasile E, Baldi GG, Stasi I, Ciarlo A, Tuzi A, Andreuccetti M, Falcone A: Bevacizumab (BV) in combination with FOLFOXIRI (Irinotecan, Oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): update results of a phase II G.O.N.O. trial. EJC Supplements. 2009, 17 (2): (suppl; poster 6081)
28.
Ficorella C, Morelli MF, Ricevuto E, Cannita K, Porzio G, Baldi PL, Cianci G, Di Rocco ZC, Natoli C, Tinari N, De Galitiis F, Calista F, Marchetti P: Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. Br J Cancer. 2004, 91: 618-20.PubMedPubMedCentral
29.
Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009, 351: 1408-17. 10.1056/NEJMoa0805019.CrossRef
30.
Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schch G, Stroh C, Loos AH, Zubel A, Koralewski P: Fluorouracil, Leucoverin, and Oxaliplatin with or without Cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009, 27: 663-671. 10.1200/JCO.2008.20.8397.CrossRefPubMed
31.
Douillard J, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel ME, Humblet Y, Cunningham D, Wolf M, Gansert JL: Randomized phase 3 study of Panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. EJC Supplements. 2009, 17: 3-(Suppl; abstact 10LBA)
32.
Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H: Association of k-ras, b-raf, and p53 status with the treatment effect of Bevacizumab. J Natl Cancer Inst. 2005, 97 (13): 981-9. 10.1093/jnci/dji174.CrossRefPubMed
33.
Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with Cetuximab: the CELIM randomized phase 2 trial. Lancet Oncol. 2009
34.
Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet. 2000, 356: 373-8. 10.1016/S0140-6736(00)02528-9.CrossRefPubMed
35.
Falcone A, Loupakis F, Cupini S, Cortesi E, Buonadonna A, Tomasello G, Banzi M, Ronzoni M, Zaniboni A, Masi G: FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO). J Clin Oncol. 2010, 28: 15s-(suppl; abstr 3543)
Metadata
Title
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study
Authors
Gemma Bruera
Alessandra Santomaggio
Katia Cannita
Paola Lanfiuti Baldi
Marianna Tudini
Federica De Galitiis
Maria Mancini
Paolo Marchetti
Adelmo Antonucci
Corrado Ficorella
Enrico Ricevuto
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-567

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas

Research article

Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer

Research article

Integration of transcript expression, copy number and LOH analysis of infiltrating ductal carcinoma of the breast

Research article

Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese

Research article

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

Research article

Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits